Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05948618 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Improving PRO for Patients With Cancer Using ECAs and Data Visualization

Study acronym: ECA-PRO Aim 3
StatusEnrolling by Invitation
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 4, 2026 (before its estimated September 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Trial status: Not Yet Recruiting to Enrolling by Invitation Start date changed from estimate of Dec 2025 to Nov 24, 2025 · Site contact updatedv5 Show 2 more changesShow less
    • Start date changed from estimate of Dec 2025 to Nov 24, 2025
    • Site contact updated
  2. Start date: Sep 2024 to Dec 2025 Site contact updatedv4 Show 1 more changeShow less
    • Site contact updated
  3. Start date: Jun 2024 to Sep 2024v3
  4. Enrollment target: 30 to 100 Primary and study completion dates: Sep 2023 to Sep 2026 · Start date: Apr 1, 2022 to Jun 2024 · Primary endpoints: 3 to 1 · 5 morev2 Show 8 more changesShow less
    • Primary and study completion dates: Sep 2023 to Sep 2026
    • Start date: Apr 1, 2022 to Jun 2024
    • Primary endpoints: 3 to 1
    • Trial status: Active, Not Recruiting to Not Yet Recruiting
    • Eligibility criteria expanded, about 35 words
    • Secondary endpoints: details revised at 7 of 7 entries
    • Study description shortened, about 9 words
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Over the past decade, the investigators have developed and tested a toll with the potential to enhance PROs at the individual level- embodied conversational agents (ECA), which are computer characters that simulate face-to-face conversation using voice, hand gestures, gaze cues, and other nonverbal behavior. The investigators have successfully used ECAs in behavioral interventions for populations with limited health literacy, elderly patients, and patients with cancer. Face-to-face encounters, in conjunction with written instructions supported by pictures, remains one of the best methods for communicating information in general but is particularly effective for individuals with limited health literacy. The investigators have also demonstrated that ECAs can be used as valid alternatives to standard paper-based surveys for substance use screening, and that the display of empathy for patients and other relational behavior by ECAs leads to increased engagement by patients over time.
Trial Details
NCT Number NCT05948618
Lead Sponsor Tufts Medical Center
Collaborators: Boston Medical Center
Conditions Cancer
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov